BSI-502, a bispecific antibody targeting TSLP and IL4R, is in the pre-clinical stage. In a completed, proof-of-concept, single-arm Phase IIa study, BSI-045B demonstrated a pharmacodynamic profile ...

The agreement includes BSI-045B, a clinical-stage anti-TSLP monoclonal antibody, and BSI-502, a pre-clinical stage bispecific antibody targeting both TSLP and IL4R. Dr. Walker highlighted the ...